Eric Weisblum
Tracked across 4 events · 25 articles · First seen Jul 07, 2026 · Last active Aug 18, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: As CEO of Silo Pharma, Eric Weisblum announced the partnership, highlighting strategic expansion into AI. His leadership is key to executing the company's diversification strategy.
Jul 14, 2026 · 7 articles
Regulatory
On August 10, 2026, Silo Pharma announced that the International — European Patent Office (EPO) granted European Patent No. EP3952852, titled 'Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress.' The patent covers methods of…
Impact: As CEO of Silo Pharma, Eric Weisblum announced the patent grant and highlighted its strategic importance. His leadership is central to the company's IP strategy and communication with investors.
Aug 10, 2026 · 6 articles
Regulatory
Silo Pharma announced that the Canada — Canadian Intellectual Property Office (CIPO) issued a Notice of Allowance for a patent application covering SPC-15, its lead intranasal 5-HT4 receptor agonist for PTSD and other stress-induced psychiatric…
Impact: Eric Weisblum, CEO of Silo Pharma, commented on the patent allowance, highlighting the company's momentum in securing international IP protection. His leadership is central to the company's strategy.
Aug 18, 2026 · 6 articles
Tech
Impact: As CEO of Silo Pharma, Weisblum announced the partnership, expressing optimism about the program's benefits for QwikAgents.
Jul 07, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Eric Weisblum live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard